An immunoradiometric assay (IRMA) for determination of antibodies against f. VIII:C in haemophilia A was developed. The assay was based on competitive binding of radiolabelled anti-VIII:C and antibodies in the test material to immobilized VIII:C. Fifteen haemophiliacs with known inhibitors were investigated with the new method and with a conventional neutralization test. In 3 cases the inhibitors were detected only with the IRMA and in the other 12 there was good agreement between the inhibitor levels found with the two methods. It was also possible to demonstrate the antibodies in three non-haemophilic patients with acquired inhibitors. The IRMA, which can detect the antibodies down to a concentration of 0.02 inhibitor units per ml, is mor...
The haemostatic effect of by-passing agents such as activated prothrombin complex concentrates (aPCC...
Factor VIII (F.VIII) and von Willebrand factor (VWF):Ag data collected by eight laboratories on a to...
The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major compli...
An immunoradiometric assay (IRMA) for the determination of factor IX inhibitors in haemophilia B was...
Inhibitors are antibodies directed against haemophilia treatment products which interfere with their...
Plasmas from 40 haemophilia A patients enrolled in a study by the paediatric group of the German Soc...
Antihaemophilic-factor-A-antibodies, which had spontaneously arisen in 2 patients, were used to deve...
Antibodies against factor VIII (FVIII) can be detected based on their ability to neutralize the proc...
A significant proportion of haemophilia A patients receiving transfusions of Factor VIII (FVIII) dev...
The treatment of patients with haemophilia A has remarkably improved over the years and the journey ...
A significant proportion of hemophilia A patients receiving transfusions of factor VIII (FVIII) deve...
In patients with hemophilia A who have an inhibitor to factor (F)VIII measured by Bethesda assay, en...
Antibody formation to factor VIII (FVIII) remains the greatest clinical and diagnostic challenge to ...
A newly developed sensitive and quantitative immunoradiometric assay (IRMA) for anti-thyroglobulin (...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
The haemostatic effect of by-passing agents such as activated prothrombin complex concentrates (aPCC...
Factor VIII (F.VIII) and von Willebrand factor (VWF):Ag data collected by eight laboratories on a to...
The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major compli...
An immunoradiometric assay (IRMA) for the determination of factor IX inhibitors in haemophilia B was...
Inhibitors are antibodies directed against haemophilia treatment products which interfere with their...
Plasmas from 40 haemophilia A patients enrolled in a study by the paediatric group of the German Soc...
Antihaemophilic-factor-A-antibodies, which had spontaneously arisen in 2 patients, were used to deve...
Antibodies against factor VIII (FVIII) can be detected based on their ability to neutralize the proc...
A significant proportion of haemophilia A patients receiving transfusions of Factor VIII (FVIII) dev...
The treatment of patients with haemophilia A has remarkably improved over the years and the journey ...
A significant proportion of hemophilia A patients receiving transfusions of factor VIII (FVIII) deve...
In patients with hemophilia A who have an inhibitor to factor (F)VIII measured by Bethesda assay, en...
Antibody formation to factor VIII (FVIII) remains the greatest clinical and diagnostic challenge to ...
A newly developed sensitive and quantitative immunoradiometric assay (IRMA) for anti-thyroglobulin (...
The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major compli...
The haemostatic effect of by-passing agents such as activated prothrombin complex concentrates (aPCC...
Factor VIII (F.VIII) and von Willebrand factor (VWF):Ag data collected by eight laboratories on a to...
The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major compli...